EW earnings date November 2026: our calendar carried November 4, 2026 as the print date for Edwards Lifesciences, and the row we published that morning had 0 days left on it. The stock closed that session at $99.37, up 4.39%, and finished November 10 at $104.01, up 20.40% on the month. It is no longer on the table we publish.

That is the good part. The honest part is that the whole medical device group moved on the same day, and Edwards Lifesciences was one of the smaller risers in it.

When does EW report earnings?

Edwards Lifesciences was due to report earnings on November 4, 2026, and that date has passed. The next print date is not on our calendar.

The row we published at 6:34 a.m. PT on November 4 is the record we have. It carried the earnings date of November 4 with 0 days left on it, a price of $98.90, and a score of 71 at rank 39 of 93. A day earlier the same row carried 1 day left, a price of $94.58 and a score of 69 at rank 46 of 100.

What we cannot tell you from our own record is whether the release had landed before the open on November 4. The headline on the row that morning was about seasonal returns, not about a release. We are not going to say the print did something we cannot confirm it did, so this piece separates what the tape did from what the calendar said.

What the print date did to the price

Edwards Lifesciences did not stop moving on November 4. It went on for five more sessions.

The stock closed October 12 at $86.39 and bottomed at $85.27 on October 13, the low close of the month. From there it climbed almost every session: $94.44 on October 29, $95.19 on November 3, then the print date. November 4 closed at $99.37, up 4.39% on the session.

The run into the date was part of the same trend. From the $91.78 close on October 28 the stock reached $94.44 on October 29, pulled back to $92.01 on October 30, then $93.26 on November 2 and $95.19 on November 3. That is a 3.71% gain into the print date.

And it kept going. November 5 closed at $100.82, up 1.46%. November 6 closed at $102.14, up 1.31%. November 9 closed at $104.71, up 2.52%, which was the high close of the month. November 10 gave back 0.67% to $104.01, the last settled close we have.

Three numbers frame it. From the October 12 close the stock is 20.40% higher. From the November 3 close before the print date it is 9.27% higher. From the high close on November 9 it is 0.67% lower. The whole range between the $85.27 low and the $104.71 high spans 22.80%, which is a wider band than the $19.44 the stock travelled from its low to its high.

Was the move the print or the sector?

On November 4 the whole medical device group went up together, and Edwards Lifesciences was the third smallest riser of the eleven names we can price.

ZBH rose 13.49% that session, ISRG 9.38%, SYK 9.37%, DXCM 6.64%, MDT 6.15%, ABT 5.59%, BDX 5.56% and BSX 5.33%. EW rose 4.39%. Only TMO at 1.12% and DHR at 2.09% rose less.

A name-specific print reaction usually shows up as an outlier in its own group. Here it was the opposite: the group moved together and EW was in the middle of it with them. The month tells a different story. From October 12 to November 10, EW is up 20.40% against ZBH at 16.44%, SYK 14.75%, BDX 12.56%, MDT 10.51%, ABT 8.49%, TMO 8.45%, DHR 6.74%, ISRG 5.24%, BSX 1.96% and DXCM down 6.98%. On the month it was the best of the group.

So the honest reading is that the group carried the print date and the name carried the month. We will not separate the two any further than the dated closes allow, and we will not put a number on the release itself, because we do not publish numbers we cannot source.

What the options market had priced in

The bands widened between the November 3 scan and the November 4 scan, and the implied move with them.

On November 3 the row carried implied volatility of 52.2 around a $94.58 price, with a three-day band of $91.01 to $98.16, a seven-day band of $89.13 to $100.04 and a fourteen-day band of $86.87 to $102.30. The straddle was $8.50 running seventeen days.

On November 4 it carried implied volatility of 58.1 around $98.90, with the three-day band at $94.74 to $103.06, the seven-day at $92.55 to $105.25 and the fourteen-day at $89.92 to $107.88. The straddle was $9.60 running sixteen days. Every band widened, and the score went from 69 to 71.

Look at where the fourteenth-day ceiling ended up. $107.88 is 3.72% above the $104.01 close on November 10, and the $89.92 floor was 15.67% below it. The options market had a bigger move on the table than the stock has delivered so far.

What the row said about the book

The analyst book tightened between the two rows without changing size.

Both rows carried 30 ratings and no sells at all. On November 3 it was 5 strong buys, 18 buys and 7 holds, which is 76.7% on the buy side. On November 4 it was 5 strong buys, 19 buys and 6 holds, which is 80.0%. Short interest was 1.7% of the float on November 3 and 1.8% on November 4, and the earnings sentiment reading was Mixed on both.

The market capitalisation moved from $54.46 billion to $56.95 billion, which is the price moving rather than the company. There is no trailing or forward multiple on either row. The table we publish each morning is readable at /open-data.

Frequently asked questions about Edwards Lifesciences

Two questions come up most often about this print, and both are answerable from the dated rows.

When did EW report, and what did the stock do?

Our calendar carried November 4, 2026 as the earnings date. The stock closed that session at $99.37, up 4.39% from $95.19, and it rose again on the three sessions after. It finished November 10 at $104.01, which is 20.40% above the October 12 close and 0.67% below the November 9 high.

How did EW compare with the rest of the medical device group?

On the print date EW rose 4.39% while ZBH rose 13.49%, ISRG 9.38%, SYK 9.37% and BSX 5.33%. Over the month to November 10 it was up 20.40%, ahead of ZBH at 16.44% and SYK at 14.75%.

Every figure here is a row we published and a close that came after it. Nothing in this piece is a forecast.